Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

1 Main Capital 2025 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (1 Main Capital)

Primary Source Intelligence • Q1 2025 Letter Analysis

1 Main Capital Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, 1 Main Capital. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD-3.6%

Annualized+19.5%

Positioning StanceConstructive

Market CapSmallCap

GeographyUS, Global

Digest Analysis

Quick Take

"1 Main Capital outperformed benchmarks in Q1 with defensive positioning in service-oriented businesses while opportunistically investing in distressed biotech companies trading below cash."

Executive Summary

1 Main Capital Partners returned -3.6% net in Q1 2025, outperforming both the S&P 500 (-4.3%) and Russell 2000 (-9.5%) during a period of market turbulence. The Fund maintains a concentrated portfolio with top five positions representing 70% of capital, including Basic-Fit, a biotech basket, dentalcorp, International Workplace Group, and Water Intelligence. Manager Yaron Naymark positioned the Fund defensively with minimal exposure to trade war-sensitive businesses, instead focusing on service-oriented companies with limited macro sensitivity. The Fund made several new biotech investments representing a low double-digit percentage of assets, targeting companies trading below cash value with engaged shareholders. Key risks include ongoing trade policy uncertainty that is causing businesses to pause discretionary spending. However, Naymark remains optimistic about medium-term prospects, believing current policies will be corrected through pressure from business leaders and politicians. The Fund announced a strategic partnership with Cannell Capital, which will invest $20 million over 18 months while providing operational support.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

75%

CautiousHigh

High Conviction (75%)

Manager demonstrates high conviction through concentrated positioning (70% in top five holdings) and specific investment decisions like biotech basket deployment. Clear articulation of investment thesis and defensive positioning strategy shows strong belief in approach.

Growth Outlook

38%

BearishBullish

Neutral (38%)

Manager expresses concern about near-term market conditions due to trade war policies and their economic impact, but maintains medium-term optimism. The outlook acknowledges current challenges while believing in eventual policy corrections.

Risk Appetite

43%

DefensiveAggressive

Balanced (43%)

Portfolio maintains defensive tilt with minimal exposure to trade war-sensitive businesses, though manager is selectively deploying capital in distressed biotech opportunities. Overall positioning reflects cautious risk management rather than aggressive deployment.

Capital Deployment

20%

De-riskingDeploying

De-risking (20%)

Manager made several new biotech investments representing low double-digit percentage of assets while reducing some trade-sensitive positions like Caesars Entertainment. Net activity suggests selective deployment rather than aggressive capital deployment or significant de-risking.

Forward Guidance

35%

CautiousExpansionary

Cautious (35%)

Manager expresses confidence in Fund's positioning and optimism about medium-term performance despite near-term concerns. Believes current policy issues will be corrected and Fund is well-positioned for strong future performance.

Language Signal

10%

BearishBullish

Bearish (10%)

Language balances concerns about trade policy impacts with confidence in portfolio positioning. Uses phrases like 'well-positioned for strong future performance' and 'should thrive in any environment' while acknowledging current challenges.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

Manager explicitly discusses trade war risks, policy uncertainty, and economic impacts on businesses. Acknowledges that current environment poses challenges for companies exposed to global supply chains, indicating moderate to high risk perception.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

Manager identifies selective opportunities in distressed biotech sector while maintaining that Fund holds businesses that should thrive in any environment. Suggests moderate opportunity set with specific areas of focus rather than broad market opportunities.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Manager emphasizes medium-term optimism over near-term concerns and focuses on businesses that should perform well over time. Partnership with Cannell Capital and concentrated positioning suggest patient capital approach with multi-year perspective.